ProQR Therapeutics (NASDAQ:PRQR) Releases Earnings Results, Beats Expectations By $0.01 EPS

ProQR Therapeutics (NASDAQ:PRQR) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01, FiscalAI reports. The company had revenue of $5.84 million during the quarter, compared to the consensus estimate of $4.30 million. ProQR Therapeutics had a negative net margin of 223.51% and a negative return on equity of 73.83%.

ProQR Therapeutics Price Performance

NASDAQ PRQR traded up $0.07 on Thursday, reaching $1.33. 558,853 shares of the company’s stock traded hands, compared to its average volume of 748,592. The stock has a market cap of $140.66 million, a PE ratio of -2.88 and a beta of 0.29. ProQR Therapeutics has a 12 month low of $1.20 and a 12 month high of $2.48. The stock has a 50-day simple moving average of $1.60 and a 200 day simple moving average of $1.68.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wall Street Zen raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, August 15th. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research note on Thursday, October 1st. Chardan Capital reaffirmed a “buy” rating and issued a $3.00 target price on shares of ProQR Therapeutics in a research note on Thursday, October 1st. Weiss Ratings upgraded shares of ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Finally, Bank of America started coverage on shares of ProQR Therapeutics in a research note on Thursday, August 20th. They issued a “buy” rating and a $8.00 price target for the company. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $7.60.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA therapies for genetic diseases. The company uses its Axiomer RNA-editing platform to investigate treatments designed to correct disease-causing genetic changes at the RNA level without permanently altering DNA. ProQR’s research has included therapies for rare inherited disorders, particularly genetic diseases affecting the eye and nervous system. Its development programs have included investigational treatments for inherited retinal diseases, while the company has also pursued partnerships and licensing opportunities to advance RNA-editing applications across additional disease areas.